“Over the last year, Khiron has seen a direct correlation between physician education and patient access. With Khiron Academy’s CPD accreditation and through our strategic partnership with Cellen Therapeutics, we are positioned to reach a growing number of medical professionals, and in turn, provide patients with greater access to medical cannabis products,” commented Tejinder Virk, President of Khiron Europe.
Khiron Academy sounds familiar, doesn’t it? If you agree, then you’re likely thinking of Khan Academy, an educational organization that has supplied free lessons to students for a variety of subjects. As someone who struggled with math and science as a kid, Khan Academy helped me scrape by. Although I was initially planning on making a cheap joke about how their names are similar, Khiron Academy and Khan Academy are alike in more ways than one. For starters, both companies are committed to continuing education toward professional development.
What is Continuing Professional Development (CPD)?
Put simply, CPD involves creating an educational space that relies on proactive methods of teaching. Compared to your typical passive and reactive teaching methods, take lectures for example, CPD focuses on combining a variety of different methodologies to learning such as training workshops, e-learning programs, conferences and events to name a few. With this in mind, CPD allows for a more personal experience and promotes the professional development of an individual.
In addition to receiving its CPD accreditation, Khiron has also partnered with Cellen Therapeutics, a leader in UK’s digital healthcare space. Khiron’s partnership with Cellen is intended to increase patient access through medical cannabis education. Furthermore, Khiron Academy will be made available to prescribers in the UK who are registered with Cellen’s education portal, MedCanHub.
“We are pleased to be joining forces with Khiron on educating prescribing specialists in the UK. Khiron is a clear global leader in medical cannabis education. We share common values in improving patient lives by educating doctors and optimizing the standard of medical care. Our aim is to create a practical guide for responsibly prescribing patients with safe and efficacious medical cannabis products,” commented Eric Bystrom, CEO of Cellen.
Additionally, Khiron Academy is available to members of the Medical Cannabis Clinicians Society (MCCS). Moreover, Khiron Academy has been essential for the training of prescribing specialists for Project21, a 20,000 patient observational study in the UK. With core operations in Latin America, Khiron has also trained numerous medical professionals in Latin America. Cumulatively, the Company has trained approximately 1000 medical professionals in Latin America and the UK.
Over the last year, physicians trained by Khiron in Latin America prescribed over 13,000 prescriptions with a compound monthly growth rate of almost 50 percent. With this in mind, Khiron has been a flagship Company for the continued development of medical cannabis education. Considering the UK is one of the fastest growing cannabis markets in Europe, Khiron Academy will be a pivotal tool for training educated and professional prescribers.
The UK has been attracting the attention of numerous cannabis companies as its cannabis market continues to explode. With this in mind, Khiron has a firm position in the European market, however, the Company will be competing with several others. How Khiron develops in Europe will likely have a noticeable impact on the Company’s performance.
Khiron’s share price opened at $0.54 today and currently sits at $0.53 indicating no significant change following the news.